🏅 FDA Orphan Designation

Retisert

Fluocinolone

Manufacturer: Bausch & Lomb Pharmaceuticals, Inc.

Indicated for:

Rare genetic disorder of the posterior segment of the eyeOrphanRare disorder of the posterior segment of the eye

FDA-Approved Indications (2)

Rare genetic disorder of the posterior segment of the eyeOrphan Designation

Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye

Rare disorder of the posterior segment of the eye

RETISERT is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye

Population: all ages

Indications & Usage

1 INDICATIONS AND USAGE RETISERT ® is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. RETISERT is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. (1)

💙 Support Programs

View all →

Retisert

Bausch and Lomb

Copay card ↗Apply ↗

Retisert

Bausch & Lomb Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.